前列地尔联合依帕司他治疗早期2型糖尿病肾病蛋白尿的临床效果
程燕，来成军
（山东省庆云县人民医院，山东 德州，253700）
浏览次数：148次 下载次数：301次
摘要：
目的 探讨前列地尔及依帕司他治疗早期2型糖尿病肾病蛋白尿的临床效果。方法 将我院2013年1月至2016年1月收治的80例早期2型糖尿病肾病蛋白尿患者分为对照组和观察组，各40例。对照组患者行常规治疗并给予前列地尔，观察组患者在对照组基础上采用依帕司他治疗，比较两组患者的临床治疗效果。结果 治疗后，观察组患者的空腹血糖（FBG）、24 h尿蛋白（24 hUAE）、血清白蛋白（ALB）、糖化血红蛋白（HbA1c）、血清肌酐（Scr）、血清尿素氮（BUN）水平均明显优于治疗前，且观察组明显优于对照组，差异均具有统计学意义（P<0.05）。治疗后，对照组患者的FBG、24 hUAE、ALB、HbA1c、Scr及BUN水平与治疗前比较，差异无统计学意义（P>0.05）。结论 前列地尔联合依帕司他治疗早期2型糖尿病肾病蛋白尿的临床效果显著，能够有效改善患者的临床症状，值得临床推广应用。
关键词：前列地尔；依帕司他；早期2 型糖尿病；蛋白尿
中图分类号：R587.2文献标志码：A文章编号：2096-1413(2017)16-0064-02
Clinical effect of alprostadil combined with epalrestat in the treatment of urine protein in early type 2 diabetic nephropathy
CHENG Yan, LAI Cheng-jun
(People`s Hospital of Qingyun County, Dezhou 253700, China)
ABSTRACT: Objective To investigate the clinical effect of alprostadil combined with epalrestat in the treatment of urine protein in early type 2 diabetic nephropathy. Methods Eighty cases of patients with urine protein in early type 2 diabetic nephropathy admitted in our hospital from January 2013 to January 2016 were selected and divided into control group and observation group, with 40 cases in each group. The control group received routine treatment and alprostadil, and the observation group accepted epalrestat on the basis of the control group. The clinical effects of the two groups were compared. Results After treatment, the levels of FBG, 24 h UAB, ALB, HbA1c, Scr and BUN of the observation group were better than those before treatment, and those of the observation group were better than the control group (P<0.05). There were no significant differences in FBG, 24 hUAB, ALB, HbA1C, Scr and BUN of the control group before and after treatment (P>0.05). Conclusion Alprostadil combined with epalrestat in the treatment of urine protein in early type 2 diabetic nephropathy has significant clinical effect, it can significantly improve the patients` clinical symptoms, which is worthy of popularization and application in clinic.
KEYWORDS: alprostadil; epalrestat; early type 2 diabetic nephropathy; proteinuria
参考文献：
[1] 周作荣,郑媛,金江丽,等.依帕司他、罗格列酮、前列地尔联合治疗糖尿病肾病的临床疗效观察[J].重庆医学,2013,42(11):1281-1283.
[2] 率红莉,汪津洋.糖尿病周围神经病变治疗药物研究进展[J].中国药房,2014,21(4):377-382.
[3] 李吉,孙家忠,李广森,等.依帕司他治疗糖尿病肾病的系统评价[J].循证医学,2014,14(5):285-290.
[4] 虞建新.联合应用前列地尔和依帕司他对糖尿病患者心率变异性影响的评价[J].中国当代医药,2014,21(12):66-67.
[5] 韩竺君,李博一.硫辛酸联合前列地尔对糖尿病心脏自主神经病变患者心率变异性的影响[J].中国医学创新,2014,11(32):37-40.
[6] 康璇.前列地尔联合依帕司他治疗早期2 型糖尿病肾病蛋白尿临床效果探讨[J].糖尿病新世界,2016,19(21):23-24.